Firebrick Pharma expanded its patent portfolio with grants in Canada and New Zealand while achieving 43% sales growth in FY26 despite steady operating expenses. The company is advancing Nasodine's commercial rollout across Southeast Asia and the US.
- Two new patents granted in Canada and New Zealand
- FY26 sales increased 43% after adjusting for one-off receipts
- Quarterly cash burn steady at $768k with $1.32m cash on hand
- Nasodine approved in Indonesia; Philippines approval pending
- Expansion of Nasodine product range and markets underway
Patent Milestones Bolster Intellectual Property
Firebrick Pharma (ASX:FRE) strengthened its intellectual property position during the June 2026 quarter by securing two significant patent grants. In May, its pandemic-use patent covering the topical application of povidone-iodine for infection prevention was accepted in Canada, joining approvals in the US, Europe, Australia, and the Philippines, with other jurisdictions pending. June saw the grant of an "Improved Virucidal Formulations" patent in New Zealand, complementing approvals in Australia and South Africa. These patents extend protection to 2040 and 2041 respectively, underpinning Firebrick's Nasodine nasal spray franchise.
Sales Growth Amid Steady Operating Costs
Firebrick reported a 43% increase in FY26 sales compared with the prior year after adjusting for a one-off $146,000 pipeline receipt in June 2025. Total cash sales for FY26 reached $227,000, reflecting growing traction especially in the US market. However, quarterly cash operating expenses edged up 2% to $839,000 in the June quarter, influenced by pre-payments for upcoming projects and some one-off costs. Net cash burn for the quarter was $768,000, consistent with an average quarterly burn of $650,000 for the year. Cash reserves stood at $1.32 million, providing approximately 1.7 quarters of runway at current burn rates.
Nasodine Commercial Expansion in Southeast Asia and the US
Nasodine Nasal Spray, Firebrick's flagship product, gained regulatory approval in Indonesia; the region's largest pharmaceutical market; during the quarter, with plans to launch sales there in FY27. The company is also pursuing approval in the Philippines, expected within the next financial year. The product is already marketed in the US and Singapore, with the US sales channel showing rapid growth. Firebrick has launched a Nasodine Throat Spray in Singapore and Fiji, with a third product anticipated later this year. Manufacturing is established in Australia, the Philippines, and the US, supporting the company's strategy to build a portfolio of nasal antiseptic products across multiple markets.
Regulatory and Market Challenges Ahead
Despite Nasodine's commercial promise as the world’s first nasal spray that kills a broad spectrum of viruses and bacteria, regulatory hurdles remain a key challenge. Many markets, including Australia, lack a clear approval pathway for nasal antiseptics, often classifying them as medicines with high evidentiary requirements. Conversely, the US permits sale as a cosmetic without therapeutic claims, facilitating easier market entry. Southeast Asian countries generally classify Nasodine as an antiseptic, enabling faster approvals. Firebrick’s licensing model targets markets with lower regulatory barriers to accelerate adoption.
Financial Position and Outlook
Firebrick’s cash position was bolstered by a $1.5 million placement in April 2026, which secured funding for at least 12 months. Management expects operating cash outflows to moderate in the coming quarter. Payments to related parties, including executive salaries and director fees, amounted to $320,000 in the June quarter. The company’s break-even sales volume is estimated at around one million Nasodine units, based on current operating costs and license fees of approximately A$2-3 per unit. While Nasodine’s retail price remains competitive, scaling sales in larger markets like the US, Indonesia, and the Philippines will be critical to achieving profitability.
Bottom Line?
Firebrick’s patent wins and steady sales growth provide a solid foundation, but scaling Nasodine’s commercial footprint amid regulatory complexities will be key to unlocking value.
Questions in the middle?
- How quickly can Firebrick expand Nasodine sales in Indonesia and the Philippines following regulatory approvals?
- Will Firebrick secure additional funding to extend its cash runway beyond 1.7 quarters if sales growth is slower than expected?
- What impact will regulatory classifications in key markets have on Nasodine’s commercial adoption and licensing partnerships?